Effect of sodium glucose cotransporter 2 inhibitors on cardiac function and cardiovascular outcome: a systematic review

K Matsumura, T Sugiura - Cardiovascular Ultrasound, 2019 - Springer
K Matsumura, T Sugiura
Cardiovascular Ultrasound, 2019Springer
A high incidence of left ventricular diastolic dysfunction and increased risk of cardiovascular
events have been reported in patients with diabetes mellitus. Sodium glucose cotransporter
2 (SGLT2) inhibitors selectively inhibit kidney glucose and sodium reabsorption, and
cardiovascular benefits of SGLT2 inhibitors beyond other antidiabetic drugs have been
reported in type 2 diabetes mellitus (T2DM) clinical trials. However, underlying mechanisms
contributing to the improvement of cardiovascular outcomes have not been clearly identified …
Abstract
A high incidence of left ventricular diastolic dysfunction and increased risk of cardiovascular events have been reported in patients with diabetes mellitus. Sodium glucose cotransporter 2 (SGLT2) inhibitors selectively inhibit kidney glucose and sodium reabsorption, and cardiovascular benefits of SGLT2 inhibitors beyond other antidiabetic drugs have been reported in type 2 diabetes mellitus (T2DM) clinical trials. However, underlying mechanisms contributing to the improvement of cardiovascular outcomes have not been clearly identified. In this review, likely mechanisms of SGLT2 inhibitors contributing to a favorable cardiovascular outcomes are discussed based on experimental and clinical studies on cardiac function.
Springer